Indication

Malignant neoplasm of gastroesophageal junction

A malignant neoplasm of the gastroesophageal junction is an aggressive cancer arising at the anatomical transition zone between the distal esophagus and the gastric cardia of the stomach. Read more about Malignant neoplasm of gastroesophageal junction

2 drugs 2 manufacturers

Advertisement

Drugs that treat it

Common Malignant neoplasm of gastroesophageal junction therapies.

Showing 1–2 of 2 drugs

OPDIVO (nivolumab)

ANTINEOPLASTIC - ANTI-PROGRAMMED DEATH-(PD-1/L1) MC ANTIBODY·MALIGNANT ESOPHAGEAL NEOPLASM·+17
BMS PRIMARYCARE
Filter & compare in the drug finder →Opens the drug finder with Malignant neoplasm of gastroesophageal junction preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Malignant neoplasm of gastroesophageal junction.

A malignant neoplasm of the gastroesophageal junction is an aggressive cancer arising at the anatomical transition zone between the distal esophagus and the gastric cardia of the stomach.

Predominantly affecting adults—with a higher incidence in older males and individuals with chronic gastroesophageal reflux disease, obesity, or Barrett esophagus—the vast majority of these tumors are adenocarcinomas.

Pathophysiologically, persistent mucosal inflammation and acid-induced intestinal metaplasia lead to dysplastic transformation, local transmural invasion, and frequent lymphatic dissemination.

Patients commonly present with progressive dysphagia, unintentional weight loss, retrosternal pain, early satiety, and anemia secondary to chronic occult blood loss.

Personalize your experience

Follow Malignant neoplasm of gastroesophageal junction and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it